MediciNova (NASDAQ: MNOV) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare MediciNova to related businesses based on the strength of its dividends, institutional ownership, risk, earnings, analyst recommendations, profitability and valuation.
This is a summary of recent ratings and price targets for MediciNova and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
MediciNova has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, MediciNova’s competitors have a beta of 2.53, meaning that their average stock price is 153% more volatile than the S&P 500.
Earnings & Valuation
This table compares MediciNova and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MediciNova Competitors||$267.94 million||-$30.77 million||-34.67|
MediciNova’s competitors have higher revenue, but lower earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares MediciNova and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
18.8% of MediciNova shares are owned by institutional investors. Comparatively, 52.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.2% of MediciNova shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
MediciNova competitors beat MediciNova on 7 of the 13 factors compared.
MediciNova Company Profile
Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.